Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
12,957 total articles
Allot Ltd., a global provider of Security-as-a-Service and network intelligence solutions, announced the filing of its annual report on Form 20-F for the year ended December 31, 2025. The report includes audited financial statements and is available on the SEC and company websites. The company serves over 500 service providers and 1000 enterprises …
Celldex Therapeutics presented positive Phase 2 clinical trial results for barzolvolimab in chronic spontaneous urticaria (CSU), cold urticaria (ColdU), and symptomatic dermographism (SD) at the 2026 AAD Annual Meeting. The data demonstrated rapid, profound, and durable improvements in patient quality of life across multiple domains, with sustained…
Aclaris Therapeutics presented additional positive Phase 2a clinical trial results for ATI-2138, an investigational oral inhibitor targeting ITK and JAK3, showing significant improvements in atopic dermatitis severity, itch, and quality of life. The therapy demonstrated strong efficacy and tolerability, supporting its potential in treating immuno-i…
Maris-Tech Ltd., a Nasdaq-listed company specializing in AI-based edge computing video solutions for defense, announced it received an order to conduct a situational awareness pilot on an armored vehicle in the U.S. The pilot integrates Maris-Tech's Diamond Ultra platform with night-vision and thermal imaging sensors to enhance battlefield awarenes…
Silynxcom Ltd. announced receiving a purchase order exceeding $1.1 million from a long-standing Middle East military customer for its ruggedized tactical communication headset devices. This order underscores the trust in Silynxcom's innovative, combat-proven tactical systems that deliver advanced communication and protective solutions in demanding …
AnaptysBio's Board has approved the spin-off of First Tracks Biotherapeutics, a clinical-stage biotech focused on autoimmune disease therapeutics. The new entity will trade on Nasdaq under ticker TRAX starting April 20, 2026. First Tracks Bio will commence operations with $180 million in cash and a robust leadership team, enabling a focused approac…
Kartoon Studios (NYSE American: TOON) will release its annual Shareholder Letter and a groundbreaking AI-animated video business update featuring company executives alongside iconic characters from its upcoming Hundred Acre Wood series. The presentation aims to demonstrate the company's innovative AI-driven animation production capabilities, which …
United-Guardian, Inc. reported a 13% decline in net sales for fiscal year 2025 to $10.5 million and a net income drop to $2.1 million, impacted primarily by reduced cosmetic ingredient sales due to distributor inventory excess and weakened demand in China amid tariffs and local competition. Positives include growth in pharmaceutical and medical lub…
SB Financial Group, Inc., a diversified financial services holding company, announced it will release its first quarter 2026 financial results on April 23, 2026, after market close. The company will hold a conference call and webcast for investors on April 24, 2026, to discuss the results. SB Financial operates community banking, mortgage banking, …
Jeffs' Brands Ltd, listed on Nasdaq, announced that its subsidiary KeepZone AI entered a non-exclusive agreement to market and distribute Skyline Software Systems' 3D GIS and photogrammetry platforms in designated territories across the Middle East, Europe, and Latin America. This partnership expands KeepZone's AI-driven security technology portfol…
Trailblazer Merger Corp. I (TBMC) announced the completion of its previously announced business combination with Cyabra Strategy, Ltd. As a result, TBMC has canceled the special meeting of stockholders that had been scheduled for March 27, 2026.
Callan JMB Inc. announced its role as an independent infrastructure and oversight partner in a collaboration to support U.S.-based manufacturing scale-up of Biostax Corp's multi-indication immune restoration platform, JKB-122 (Lodonal™). The collaboration advances the platform toward Phase 2b/3 clinical development, ensuring compliance and readines…
20/20 BioLabs, Inc. has received over $520,000 in funding from the Maryland Department of Health to provide its patented OneTest™ multi-cancer early detection blood test to more than 1,400 firefighters across 18 Maryland fire departments. This represents a significant increase in screenings compared to the prior year and reflects growing public sec…
Hudson Technologies has signed a licensing agreement with Solstice Advanced Materials to reclaim and resell patented HFO refrigerants R-448A and R-449A in the U.S. and Canada. This move enhances Hudson's presence in the commercial refrigeration market amidst regulatory phase-downs of higher GWP refrigerants, aligning with efforts to provide sustain…
Jyong Biotech Ltd., listed on Nasdaq as MENS, announced updates on its plant-derived drug candidate MCS®-2, emphasizing its clinical advantages in treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). The drug has completed multiple Phase III trials in the US and Taiwan with strong safety and efficacy profiles, and ho…
One and One Green Technologies. INC (NASDAQ: YDDL), a licensed hazardous waste recycler in the Philippines, announced a new business venture to recover copper-gold ore tailings slag in Luzon. This strategic initiative targets the projected global copper supply deficit of 150,000 metric tons in 2026 by partnering with local small-scale miners and le…
ORIC Pharmaceuticals announced plans to report combination dose optimization data from its Phase 1b trial of rinzimetostat in metastatic castration resistant prostate cancer patients. The presentation will occur during a webcast and conference call on March 31, 2026. This update provides insights into dosing strategies for an investigational allost…
BranchOut Food Inc., a food technology company specializing in natural fruit and vegetable snacks using its proprietary GentleDry process, announced a conference call to discuss its Q4 and full-year 2025 financial results along with a corporate and shareholder update scheduled for March 31, 2026. The company highlighted its patented dehydration tec…
Ocean Power Technologies announced securing a contract to deliver a fully integrated WAM-V autonomous surface vehicle to a new underwater research customer in the Nordics. This order marks an expansion of the company's presence in the Nordic region and demonstrates ongoing demand across multiple sectors including defense, surface inspections, and u…
Cyabra, a company dedicated to identifying coordinated manipulation in online narratives and protecting digital trust, has completed its business combination with Trailblazer Merger Corp. Cyabra's common stock is set to begin trading on Nasdaq on March 27, 2026, under the ticker CYAB. The combination supports Cyabra's mission to combat disinformati…
Quantum BioPharma Ltd. announced its audited financial results for 2025 showing a strong balance sheet with $11.3 million in cash and digital assets, improved working capital, and reduced operating expenses. The company completed Phase 1 toxicology studies for its oral MS drug candidate Lucid-MS, advancing toward Phase 2 trials. Additionally, clini…
Inflection Point Acquisition Corp. VI, a special purpose acquisition company (SPAC), announced the pricing of its IPO, offering 22 million units at $10 each, expected to raise $220 million. The units will trade on Nasdaq under ticker IPFXU, with separate trading expected for shares and warrants under IPFX and IPFXW respectively. The company aims to…
Hydrofarm Holdings Group, Inc. announced its fourth quarter and full year 2025 financial results showing a 32.7% reduction in net sales for Q4 compared to the prior year, driven by industry oversupply and price decreases. Despite improvements in gross profit margins and reduced operating expenses due to restructuring efforts, the company reported a…
Glucotrack, Inc. announced significant progress towards filing an Investigational Device Exemption (IDE) with the U.S. FDA in Q2 2026 to initiate a U.S. clinical trial for its implantable continuous blood glucose monitoring system. Following successful first-in-human trials in Brazil and a follow-up study in Australia, the company completed key tri…
Senti Biosciences announced its fourth quarter and full year 2025 financial results, marking significant progress in its clinical pipeline, particularly with SENTI-202 for relapsed/refractory acute myeloid leukemia (AML). The company reported positive preliminary Phase 1 clinical data, received FDA Regenerative Medicine Advanced Therapy designation…
